ClinicalTrials.gg
RecruitingNCT06421675EMBRACEUpdated Sep 28, 2026

Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma

A Phase 2 interventional study of Elranatamab injection in Refractory Multiple Myeloma, sponsored by Ontario Clinical Oncology Group (OCOG). Recruiting at 6 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Ontario Clinical Oncology Group (OCOG) · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.
Updated Sep 28, 20261 site added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies testing elranatamab in Multiple Myeloma — 21 open to participants now, 25 under way, 5 of them phase 3. elranatamab · Multiple Myeloma.

Planned enrollment
22nd of 31
40 · median 75
Started
2025
with 8 others
Phase 2
18 of 31
12 open now
Primary completion
2026-12
later than 3 of 24 live
Registered
18th of 31
by date

Among the 31 studies testing elranatamab in Multiple Myeloma, this one is the 22nd largest by planned enrollment, is one of 9 that started in 2025, is one of 18 in phase 2, reaches primary completion later than 3 of the 24 other live ones, and was the 18th registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

21 of the 31 studies testing elranatamab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About elranatamab

elranatamab: first FDA approval 2023 (ELREXFIO), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing elranatamab in Multiple Myeloma, or all of them as a file.
02

Study summary

A phase II study of single agent elranatamab in patients with relapsed and/or refractory multiple myeloma (MM) who have previously received at least three classes of therapeutic agents and are refractory to the last line of treatment. The primary objective of this study is to improve the tolerability and safety of elranatamab in patients with relapsed and/or refractory multiple myeloma by evaluating an outpatient and intermittent dosing strategy.

Read the detailed description

This is a multi-centre, single arm, phase II study of single agent elranatamab in patients with relapsed and/or refractory multiple myeloma (MM) who have previously received at least three classes of therapeutic agents and are refractory to the last line of treatment. Potential study participants must have documented evidence of refractory or progressive disease during or within 60 days (measured from the end of the last cycle) of completing treatment with the last anti-myeloma drug regimen used just prior to study entry. Study participants will receive SC administration of elranatamab until disease progression, unacceptable toxicity or death. The primary short term outcome is hospitalization rate within the first 2 weeks of Cycle 1 of treatment; the primary long term outcome is rate of grade 3+ infections within the first 24 months of treatment. Study participants will be followed for survival for 36 months from the date of enrollment. A total of 40 study participants will be enrolled across approximately 5 Canadian clinical trial sites.

03

Conditions studied

  • Refractory Multiple Myeloma

Keywords

  • relapsed
  • refractory
  • multiple myeloma
  • elranatamab
  • cytokine release syndrome
  • immune effector-cell associated neurotoxicity
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. MM defined as:

    1. Documented evidence of progressive disease (PD) after achieving at least minimal response (MR) for ≥ 1 cycle during a previous MM treatment (i.e., relapsed MM).
    2. Disease progression during or within 60 days from the end of the most recent MM treatment (i.e., refractory MM).
  2. based on IMWG criteria, defined as at least one of the following, documented within 28 days before enrollment:

    1. Serum M-protein ≥ 0.5 g/dl.
    2. Urine M-protein excretion ≥ 200 mg/24 h.
    3. Serum-free light chains (FLC) assay: Involved FLC level ≥ 10 mg/dl (≥ 100 mg/l) AND an abnormal serum-free light chain ratio (\< 0.26 or > 1.65) only for patients without measurable serum or urine M protein.
  3. Receipt of at least three prior classes of drugs either in separate regimens or as combinations.

    The three classes are defined as:

    An immunomodulatory drug (lenalidomide or pomalidomide), a proteasome inhibitor (bortezomib, ixazomib, carfilzomib), and an anti-CD38 drug (daratumumab or isatuximab).

  4. At least 18 years of age.
  5. (ECOG) performance status score of ≤2.

Exclusion criteria

Exclusion Criteria:

Medical conditions

  1. Active plasma cell leukemia (either 20% of peripheral white blood cells or > 2.0 × 109/L circulating plasma cells by standard differential).
  2. Amyloidosis.
  3. POEMS syndrome (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal plasma cell disorder, Skin Changes).
  4. Monoclonal gammopathy of unknown significance or smoldering multiple myeloma.
  5. Solitary plasmacytoma.
  6. Stem cell transplant within 12 weeks prior to enrollment or active .
  7. History of prior treatment with a BCMA targeting agent.

    Laboratory Parameters

  8. Laboratory results within 28 days as per below prior to enrollment:

    • (ANC) ≤ 1.0 x 109 /L) (use of growth factor is permitted if completed at least 7 days prior to enrollment).
    • count ≤ 25 x 109 /L (transfusion support permitted if completed at least 7 days prior to enrollment).
    • ≤ 8.0 g/dL (transfusion support permitted if completed at least 7 days prior to enrollment, concurrent erythropoietin stimulating agents allowed).
    • Serum and ALT > 2.5 x (ULN).
    • \< 30 mL/min (according to the Cockcroft Gault formula, by 24-hour urine collection for creatinine clearance, or according to local institutional standard method).
    • Total > 2.0 x ULN (≥ 3.0 unless known to have Gilbert's disease).

    Support Requirement

  9. As this protocol requires outpatient administration, the patient will be excluded if they cannot agree to the following for the first 9 days post-first dose of drug administration:

    1. Staying within 60 minutes of travel distance to their trial-based hospital.
    2. Must have a caregiver/support person who will stay with the patient.
    3. Patient and/or their caregiver/support person agree to monitor and record oral temperature q8 hours.
    4. Patients must agree that if they have an oral temperature of (≥38°C), they must report to the study team within 1 hour and can come to the hospital for admission within 2 hours.

    Other co-morbidities

  10. Impaired cardiovascular function or cardiovascular diseases, defined as any of the following within 6 months before enrollment:

    • Acute myocardial infarction or acute coronary syndromes (eg, unstable angina, coronary artery bypass graft, coronary angioplasty or stenting, symptomatic pericardial effusion).
    • Clinically significant cardiac arrhythmias (eg, uncontrolled atrial fibrillation or uncontrolled paroxysmal supraventricular tachycardia).
    • Thromboembolic or cerebrovascular events (eg, , cerebrovascular accident, deep vein thrombosis [unless associated with a central venous access complication], or pulmonary embolism).
    • Prolonged syndrome (or triplicate average QTcF >470 msec at screening).
  11. Ongoing Grade ≥2 peripheral sensory or motor neuropathy.
  12. History of Guillain-Barre Syndrome (GBS) or GBS variants, or history of any Grade ≥3 peripheral motor polyneuropathy.
  13. Unresolved acute effects of any prior therapy for MM in the last three months to either baseline severity or ≤Grade 1.
  14. Active , , SARS-CoV2, , or any active, uncontrolled bacterial, fungal, or viral infection.
  15. Any other active within 2 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ.
  16. Any serious and/or unstable pre-existing medical, psychiatric disorder, or other conditions (including lab abnormalities), or surgical (major surgery within 14 days prior to enrollment) that could interfere with the patient's safety, obtaining or compliance to the study procedures.
  17. Known immediate or delayed reaction or idiosyncrasy to drugs chemically related to elranatamab or any of the components of the study treatment.

    Concomitant Medications

  18. Treatment with a chemotherapeutic or anti-MM drug within the last 28 days or 5 half-lives (whichever is shorter) prior to enrollment or are currently enrolled in another interventional clinical study.
  19. Receipt of any other therapy to treat cancer (including radiation, biologics, cellular therapies, and/or at doses > 20 mg dexamethasone or equivalent) within 14 days prior to the enrollment.
  20. Receipt of any within 30 days prior to enrollment or expected need of live vaccination during study participation. (Administration of locally approved non-live vaccine can be done as per local guidelines during the screening and/or treatment period including the COVID-19 mRNA vaccine. Elranatamab should be administered ± 7 days from the SARS-CoV-2 vaccine administration).

    Pregnancy and

  21. Pregnancy or lactating female or inability of female patients of (FCBP) to meet contraception requirements (see Section 5.1.3.).

    Informed Consent

  22. Inability to provide signed, informed consent.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Elranatamab injection

    The administration of two step-up elranatamab doses (12 mg and 32 mg) and full dose 76 mg. The dosing interval for the first Cycle (each cycle q28 days) is every week. Cycles 2-3, the dosing interval increases to q2weeks. Cycles 4-12, the dosing interval increases to q4weeks. Cycles 13+, further dosing interval increases to q8weeks will be scheduled if a participant meets criteria for IMWG complete response (CR) in Cycle 12 (bone marrow required at Cycle 12 to confirm). If a participant does not meet CR criteria at Cycle 12, they will be continued on Q4W dosing.

    Drug: Elranatamab injection

Interventions

  • DrugElranatamabStudies of ElranatamabElranatamab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Elranatamab (Elrexfio) is a humanized bispecific antibody that targets both BCMA-expressing multiple myeloma (MM) cells and CD3-expressing T cells.

    Also known as: Elrexio

06

What researchers measure

Primary outcomes

  1. Hospitalization rate

    Hospitalization rate, defined as the number of patients who are hospitalized within the first 2 weeks of Cycle 1 of treatment, due to any cause, divided by the number of patients who are treated with elranatamab.

    Time frame: 2 weeks

  2. Rate of grade 3+ infections

    Rate of grade 3+ infections as grade by NCI CTCAE v5 within the first 24 months of treatment, defined as the number of patients who experience a grade 3+ infection within 24 months of treatment, divided by the number of patients who are treated with elranatamab.

    Time frame: 24 months

Secondary outcomes

  1. Overall response rate.

    Overall response rate, defined by the IMWG criteria.

    Time frame: 36 months

  2. Progression free survival.

    PFS, defined as the time from the date of first dose until confirmed PD per IMWG criteria or death due to any cause, whichever occurs first.

    Time frame: 36 months

  3. Duration of response.

    DOR is defined, for participants with an overall response per IMWG criteria, as the time from the first documentation of overall response that is subsequently confirmed, until confirmed PD per IMWG criteria, or death due to any cause, whichever occurs first.

    Time frame: 36 months

  4. Time to response.

    TTR is defined, for participants with an overall response per IMWG criteria, as the time from the date of first dose to the first documentation of overall response that is subsequently confirmed.

    Time frame: 36 months

  5. Adverse Events

    AEs will be graded according to NCI CTCAE Version 5. CRS and ICANS will be assessed. AEs will be characterized by type, frequency, severity, timing, seriousness, and relationship to elranatamab. AEs will be presented with and without regard to causality based on the investigator's judgment. The frequency of overall toxicity, categorized by toxicity Grades 1 through 5, will be described. Additional summaries will be provided for AEs that are observed with higher frequency and for AESIs (including CRS and ICANS).

    Time frame: 36 months

  6. Clinical laboratory data

    Clinical laboratory data will be classified by grade according to NCI CTCAE version 5.0 and will be analyzed using summary statistics. The worst on-treatment grades during the treatment period will be summarized.

    Time frame: 36 months.

  7. Overall survival

    OS, defined from the date of study registration to the date or death due to any cause.

    Time frame: 36 months

  8. Patient Frailty

    Frailty will be measured using the IMWG frailty score and the time for the 4-meter walk test will be recorded.

    Time frame: To the time of disease progression.

  9. Frequency and Timing of Hospitalization

    Frequency and timing hospitalization will be recorded during the first two weeks of the study treatment.

    Time frame: 2 weeks.

  10. Patient Quality of Life

    QoL during treatment measured using the EORTC QOL Questionnaire-C30 instrument EORTC QLQ-C30

    Time frame: To the time of disease progression.

Other outcomes

  1. Exploratory outcome BCMA expression (biologic tumor characteristics)

    BCMA levels in blood and their relationship to clinical response and progression.

    Time frame: 36 months

  2. Feasibility, adherence and satisfaction of remote patient monitoring

    Feasibility, adherence and satisfaction of remote patient monitoring during the first 9 days of treatment using an outpatient remote monitoring device

    Time frame: First 9 days of treatment.

  3. Patient satisfaction with the use of the remote monitoring device

    Patient satisfaction with the use of the remote monitoring device will be captured using a single, 5-point likert scale question, asked when the device is returned.

    Time frame: First 9 days of treatment.

07

Study locations

6 of 6 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Dec 2026, 21 months after the start.

Of 411 non-industry phase 2 interventional studies under Multiple Myeloma, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 96. This study's planned 21 months is below that.

Counting every sponsor, half of 504 studies reached it within 57 months; a quarter within 35 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2024
First posted
May 20, 2024
StartActual
Mar 28, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2028
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Bc Cancer - Victoria · Victoria, Canada
Show 1 removed
  • London Health Science Centre - Victoria Hospital · London, Canada
Sep 28, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • London Health Science Centre - Victoria Hospital · London, CanadaContact added M•••@lhsc.on.ca · •••8500
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    1 site added, 1 site removed
    Show site
    • Bc Cancer - Victoria · Victoria, Canada
    Show 1 removed
    • London Health Science Centre - Victoria Hospital · London, Canada
    Site contacts Changed at 1 site. See the sites
    Show the site
    • London Health Science Centre - Victoria Hospital · London, CanadaContact added M•••@lhsc.on.ca · •••8500
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06421675
Lead sponsor
Ontario Clinical Oncology Group (OCOG)
Responsible party
Sponsor
First posted
May 20, 2024
Start date
Mar 28, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2028 (estimated)
Last update
Sep 28, 2026

Study contacts

Emilio Aguirre, CRA,HIT,CHIM
Contact
aguirre@mcmaster.ca
905-527-2299 ext. 42650
Daryl Solomon
Contact
solomd5@mcmaster.ca
905-527-2299 ext. 42622
Hira Mian, MD
principal investigator · McMaster University
Jim Wright, MD
study director · OCOG - McMaster University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elranatamab

Start the discussion